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Boudreau A, Richard AJ, Burrell JA, King WT, Dunn R,
Schwarz JM, Ribnicky DM, Rood J, Salbaum JM, Stephens JM.
An ethanolic extract of Artemisia scoparia inhibits lipolysis in vivo
and has antilipolytic effects on murine adipocytes in vitro. Am J
Physiol Endocrinol Metab 315: E1053–E1061, 2018. First published
August 28, 2018; doi:10.1152/ajpendo.00177.2018.—An ethanolic
extract of Artemisia scoparia (SCO) has metabolically favorable
effects on adipocyte development and function in vitro and in vivo. In
diet-induced obese mice, SCO supplementation significantly reduced
fasting glucose and insulin levels. Given the importance of adipocyte
lipolysis in metabolic health, we hypothesized that SCO modulates
lipolysis in vitro and in vivo. Free fatty acids and glycerol were
measured in the sera of mice fed a high-fat diet with or without SCO
supplementation. In cultured 3T3-L1 adipocytes, the effects of SCO
on lipolysis were assessed by measuring glycerol and free fatty acid
release. Microarray analysis, qPCR, and immunoblotting were used to
assess gene expression and protein abundance. We found that SCO
supplementation of a high-fat diet in mice substantially reduces
circulating glycerol and free fatty acid levels, and we observed a
cell-autonomous effect of SCO to significantly attenuate tumor necrosis factor-␣ (TNF␣)-induced lipolysis in cultured adipocytes. Although several prolipolytic and antilipolytic genes were identified by
microarray analysis of subcutaneous and visceral adipose tissue from
SCO-fed mice, regulation of these genes did not consistently correlate
with SCO’s ability to reduce lipolytic metabolites in sera or cell
culture media. However, in the presence of TNF␣ in cultured adipocytes, SCO induced antilipolytic changes in phosphorylation of
hormone-sensitive lipase and perilipin. Together, these data suggest
that the antilipolytic effects of SCO on adipose tissue play a role in the
ability of this botanical extract to improve whole body metabolic
parameters and support its use as a dietary supplement to promote
metabolic resiliency.
adipocyte; Artemisia scoparia; botanical; lipolysis

dysfunction that accompanies obesity and type 2 diabetes (64).
Adipose tissue lipolysis, the process by which adipocytes
release fatty acids and glycerol into the circulation, occurs in
response to a variety of stimuli, including fasting. Insulin
resistance and obesity are often associated with abnormally
high rates of basal lipolysis in the fed state, resulting in
elevated circulating fatty acid levels that can further promote
insulin resistance and impair metabolic functions in several
tissues (41).
Plants have a long history of medicinal use in many cultures,
and many modern pharmaceuticals have been developed from
botanical sources. Screening efforts in our laboratory identified
an ethanolic extract of Artemisia scoparia (SCO) that promotes
adipocyte development in vitro (49). Subsequent studies revealed that SCO is a highly specific activator of peroxisome
proliferator-activated receptor-␥ (PPAR␥) but not of any other
nuclear receptor (47). In vivo, SCO, administered by oral
gavage or through diet supplementation, exerts metabolically
beneficial effects such as improved whole body insulin sensitivity and reduced circulating triglycerides and adiponectin, as
well as many favorable effects on adipose tissue, including
enhanced endocrine function and insulin signaling, and reduced monocyte chemoattractant protein-1 (MCP-1) levels,
while producing no changes in body weight, food intake, body
composition (47, 49, 65), fat pad weight independent of depot
(observed, data not published), or de novo lipogenesis in liver
or adipose tissue (52). In vitro, experiments in 3T3-L1 cells
have also demonstrated SCO’s ability to enhance adipogenic
differentiation and to reduce tumor necrosis factor-␣ (TNF␣)induced changes in inflammatory gene expression and adipokine secretion (49). Given the important role of lipolysis in
insulin resistance and metabolic health (41), we hypothesized
that SCO might be able to modulate adipocyte lipolysis.

INTRODUCTION

Once regarded simply as a storage site for excess energy,
adipose tissue is now known to be a major regulator of
metabolic health (32). Disruption of adipose tissue’s ability to
store lipid or to respond to insulin, or dysregulation of its
endocrine functions, have all been implicated in the metabolic
Address for reprint requests and other correspondence: J. Stephens, Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins
Rd., Baton Rouge, LA 70808 (e-mail: jsteph1@lsu.edu).
http://www.ajpendo.org

MATERIALS AND METHODS

Animals and extract preparation. SCO was grown under common
greenhouse conditions at Rutgers University and harvested as the total
plant above soil level during late-stage flowering, when seeds are
beginning to develop. The ethanolic extract used for diet formulation
and cell culture experiments was prepared as previously reported (49).
C57BL/6J diet-induced obese (DIO) mice were purchased from Jackson Laboratories (Bar Harbor, ME), housed, randomized, and fed as
described (in Ref. 49) with Research Diets [New Brunswick, NJ;
high-fat diet (HFD) D12492 (60% kcal as fat)] with or without 1%
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wt/wt SCO supplementation. Mice had ad libitum access to assigned
diets and water for 4 wk. Two separate cohorts of mice from this
feeding study were used. Treatment of the two cohorts differed only
at the end of study on day 28/29 of defined diet feeding. For cohort 1,
which was used for determination of circulating glycerol and fatty
acids, on day 29, food was removed between 1200 and 1745, and
lights were turned off at 1800. At 2200, animals were euthanized, and
blood was collected. Blood samples were centrifuged at 3,500 rpm for
15 min, and the serum was separated, aliquoted, and frozen at ⫺80°C
until time of analysis. For cohort 2, which was used for gene and
protein expression analyses of adipose tissue (by microarray, qPCR,
and immunoblotting), animals were euthanized on day 28, after a 4-h
fast starting at 0630. All animal studies were approved by the
Pennington Biomedical Research Center Institutional Animal Care
and Use Committee (Protocol no. 665P).
Serum fatty acids and glycerol. Serum lipids were extracted using
2:1 chloroform-methanol based on the Folch method (12). After total
lipid extraction, the chloroform layer was dried under nitrogen and
resuspended in 1 ml of chloroform and 1 mL of 3N methanolic HCl.
Tubes were incubated at 37°C overnight. After incubation, 2 ml of 5%
NaCl and 3 ml of hexane were added to the tubes and vortexed. The
top layer was used for fatty acid analysis, and the lower layer was used
for glycerol analysis. The nonaqueous layer containing the fatty acids
was dried under nitrogen and resuspended in hexane for GC-MS
analysis. The aqueous phase containing the glycerol was processed
using a series of cation and anion columns and then dried using a
Speed Vac. The sample was then derivatized using 100 l of pyridine:
acetic anhydride (1:2). Samples were heated at 60°C for 30 min, dried
under nitrogen, and then resuspended in ethyl acetate for analysis by
GC-MS (Agilent, Santa Clara, CA) (52).
Cell culture and lipolysis measurements. Murine 3T3-L1 preadipocytes were grown and differentiated as previously described (6).
Fully differentiated 3T3-L1 adipocytes were pretreated in their regular
medium [Dulbecco’s modified Eagle’s medium (DMEM; SigmaAldrich, St. Louis, MO) plus 10% fetal bovine serum (FBS; Hyclone,
GE Life Sciences, Logan, UT)] with 50 g/ml SCO for 72–96 h and
0.5– 0.75 nM TNF␣ (Life Technologies, Carlsbad, CA) for 16 h, or
respective vehicle controls. Stock solutions were at 50 mg/ml in
DMSO for SCO, and 0.5 M in phosphate-buffered saline (PBS) plus
0.1% bovine serum albumin (BSA, Sigma-Aldrich) for TNF␣. In each
case, equal volumes of stock solutions and their respective vehicles
were used. After pretreatment, medium was removed, and cells were
incubated in phenol red-free DMEM (Life Technologies) containing
0.1% glucose and 2% BSA for 2.5 h. Conditioned media were
collected and assayed for glycerol by use of free glycerol reagent
(Sigma-Aldrich), or for nonesterified fatty acids (NEFA) by use of a
free fatty acid (FFA) quantification kit (BioVision, Milpitas, CA).
Absorbances were measured on a Versa Max spectrophotometer using
Spectromax software (Molecular Devices, Sunnyvale, CA).
Microarray analysis of gene expression. Inguinal (iWAT) and
epididymal (eWAT) adipose tissue depots from mice fed a HFD with
or without SCO supplementation for 4 wk (as described above) were
harvested and flash-frozen. RNA was then purified using the RNeasy
mini kit (Qiagen, Hilden, Germany), and reverse transcribed using
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA). Gene
expression analysis of SCO-exposed compared with nonexposed samples was performed as described previously (26), using Illumina
mouse expression arrays (Illumina, San Diego, CA) and following
protocols specified by the manufacturer. Briefly, raw array data were
extracted and processed by Limma software (51), which included
background subtraction, identification of expressed genes, quantile
normalization, and log2 transformation. Differentially expressed
genes were identified through a Bayesian-moderated t-test (yielding
Bayes-regularized P values), as implemented in CyberT software
(29). Data were deposited to the Gene Expression Omnibus (GEO)
database (accession no. GSE113808). Results were examined for
effects of SCO on a list of 36 genes selected on the basis of literature

searches for their involvement in lipolysis (shown in Table 1). Genes
with P values below 0.05 were considered differentially expressed.
Quantitative polymerase chain reaction gene expression analysis.
A subset of SCO-regulated genes identified in iWAT and eWAT by
microarray analysis was validated by quantitative polymerase chain
reaction (qPCR) analysis using RNA prepared as described above. For
in vitro studies, cells were harvested, and RNA was isolated using the
RNeasy mini kit. Reverse transcription was performed with the
High-Capacity cDNA Reverse Transcription kit (Applied Biosystems,
Foster City, CA). Takara SYBR premix (Takara Bio USA, Mountain
View, CA) and primers from IDT (Integrated DNA Technologies,
Skokie, IL) were used to perform qPCR on the Applied Biosystems
7900 HT system with SDS 2.4 software (Applied Biosystems). Thermal cycling conditions were as follows: 2 min at 50°C, 10 min at
95°C, 40 cycles of 15 s at 95°C, and 1 min at 60°C; dissociation stage:
15 s at 95°C, 15 s at 60°C, and 15 s at 95°C. Nono (non-POU domain
containing octamer-binding protein) and Ppia (peptidylprolyl isomerase A) were used as reference genes. Primer sequences are shown in
Table 2.
Whole cell extract preparation. Adipocyte monolayers from experiments described above were harvested in a buffer containing 150 mM
NaCl, 10 mM Tris (pH 7.4), 1 M ethylene glycol tetraacetic acid
(EGTA), 1 mM ethylenediaminetetraacetic acid (EDTA), 1% Triton
X-100; 0.5% Igepal CA-630, 1 mM phenylmethylsulfonyl fluoride, 1
M pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 M
leupeptin, 1 mM 10-phenanthroline, and 0.2 mM sodium orthovana-

Table 1. List of lipolysis-related genes used to query
microarray data from SCO feeding study
Gene Name

Gene Symbol

References*

Abhydrolase domain containing 5
Adenosine A1 receptor
Adenosine A2b receptor
Adrenoceptor alpha 1A
Adrenoceptor alpha 1B
Adrenoceptor alpha 2A
Adrenoceptor alpha 2B
Adrenoceptor alpha 2C
Adrenoceptor beta 1
Adrenoceptor beta 2
Adrenoceptor beta 3
Aquaporin 7
Arrestin beta 1
Caveolin 1
Endothelin 1
Free fatty acid receptor 2
G0/G1 switch 2
Hydroxycarboxylic acid receptor 2
Leptin
Lipase, hormone sensitive
Mitogen-activated protein kinase kinase kinase 8
Melanocortin 2 receptor
Melanocortin 5 receptor
Monoglyceride lipase
Natriuretic peptide receptor 1
Natriuretic peptide receptor 2
Natriuretic peptide receptor 3
OPA1, mitochondrial dynamin like gtpase
Phosphodiesterase 3b
Phosphodiesterase 4a
Phosphodiesterase 4b
Phosphodiesterase 4d
Phosphodiesterase 5
Perilipin
Patatin-like phospholipase domain containing 2
Succinate receptor 1

Abhd5
Adora1
Adora2b
Adra1a
Adra1b
Adra2a
Adra2b
Adra2c
Adrb1
Adrb2
Adrb3
Aqp7
Arrb1
Cav1
Edn1
Ffar2
G0s2
Hcar2
Lep
Lipe
Map3k8
Mc2r
Mc5r
Mgll
Npr1
Npr2
Npr3
Opa1
Pde3b
Pde4a
Pde4b
Pde4d
Pde5
Plin
Pnpla2
Sucnr1

(13)
(7)
(7)
(13)
(13)
(13)
(13)
(13)
(9, 18)
(9, 18)
(9, 18)
(13)
(9, 28)
(13)
(25)
(15)
(23)
(69)
(19)
(9, 31)
(21)
(40)
(40)
(13)
(7)
(7)
(7)
(10)
(9, 45, 68)
(34)
(34)
(34)
(3)
(9, 53)
(9, 31)
(38)

SCO, Artemisia scoparia. *References that refer to a gene as playing a role
in lipolysis.
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Table 2. Primer sequences for quantitative PCR gene expression analysis
Gene Name (Symbol)

Forward Primer, 5=-3=

Reverse Primer, 5=-3=

Cyclophilin A (Ppia)
Non-POU domain containing octamer binding protein (Nono)
Perilipin 1 (Plin1)
Phosphodiesterase 3b (Pde3b)
G0/G1 switch 2 (G0s2)
Hormone-sensitive lipase (Lipe)
Patatin like phospholipase domain containing 2 (Pnpla2/Atgl)
Adrenergic receptor, beta 3 (Adrb3)

CCACTGTCGCTTTTCGCCGC
CATCATCAGCATCACCACCA
CGTGGAGAGTAAGGATGTCAATG
GTCGTTGCCTTGTATTTCCC
CAAAGCCAGTCTGACGCAA
CTGCAAGAGTATGTCACGCTA
GAGCTCATCCAGGCCAAT
CCACCGCTCAACAGGTTT

TGCAAACAGCTCGAAGGAGACGC
TCTTCAGGTCAATAGTCAAGCC
GTGCTGTTGTAGGTCTTCTGG
CAACTCCATTTCCACCTCCA
CCTGCACACTTTCCATCTGA
CTCGTTGCGTTTGTAGTGC
CTCATAAAGTGGCAAGTTGTCTG
CCAGAAGTCCTGCAAAAACG

RESULTS

CON

0.03

SCO

**

*

*

6

0.02
4

*
0.01

2

*
0.00

glycerol (mmol/mg plasma)

On the basis of our previous studies, we hypothesized that
SCO might affect another important metabolic pathway in
adipose tissue, namely lipolysis. First, we examined the levels
of FFAs and glycerol in serum of mice fed HFD (60% kcal as
fat) for 4 wk in the presence or absence of 1% (wt/wt) of SCO
extract. As shown in Fig. 1, supplementation with SCO significantly reduced the circulating levels of glycerol and of all fatty
acids measured (C18:0, C18:1, C16:0, C16:1), suggesting that
SCO may have direct effects on adipose tissue to reduce
lipolysis.
The relationships between inflammation, lipolysis, and insulin resistance (11, 27, 44) prompted us to examine whether
SCO could affect lipolysis under basal and induced conditions
in a cell-autonomous manner in adipocytes. We stimulated
lipolysis either with TNF␣ or by ␤-adrenergic stimulation with
isoproterenol in murine 3T3-L1 adipocytes. As shown in Fig.
2, TNF␣ and isoproterenol strongly induced lipolysis, as measured by both glycerol and FFA release into the culture
medium. Chronic pretreatment (72 h) with SCO had no significant effects on basal or isoproterenol-induced lipolysis, but
significantly attenuated the effect of TNF␣.
To investigate the potential mechanisms by which SCO may
be modulating lipolysis, we performed microarray analysis on

visceral eWAT and subcutaneous iWAT samples from male
mice fed a HFD with or without SCO supplementation. The
resulting data were examined for effects of SCO on 36 genes
known to be involved in lipolysis. The list of genes queried is
shown in Table 1; genes from this list found to be regulated by
SCO (P ⬍ 0.05; 10 in iWAT, 8 in eWAT), and their corresponding fold changes, are shown in Table 3. Expression of
some of these genes was regulated in a manner that would be
expected to reduce lipolysis. For example, Lipe/Hsl and Adrb3
(␤3-adrenergic receptor) are both downregulated in iWAT and
eWAT, and Pde3b is downregulated in iWAT. However, the
effect of SCO on other genes could be considered prolipolytic.
One example is the reduced expression of G0s2 in iWAT. A
subset of the SCO-regulated genes was analyzed by qPCR to
validate the microarray results (Fig. 3). All genes evaluated
were regulated in the same direction as observed in the microarray analysis, although not all of the SCO-induced changes
were statistically significant when analyzed by qPCR.
Stimulation of lipolysis by TNF␣ is associated with the
inhibition of several antilipolytic genes including Plin, Pde3b,
and G0s2 (23, 45, 67). Hence, we measured the effects of
TNF␣ and SCO on the expression of these genes in 3T3-L1
adipocytes. As shown in Fig. 4, we observed the expected
reductions in expression with TNF␣ treatment. However, SCO
did not reverse these changes, suggesting that the effect of
SCO on TNF␣-mediated lipolysis is likely independent of the
transcriptional regulation of these genes. Although TNF␣ pro-

Fatty acids (%by weight)

date. Lysates were subjected to one freeze-thaw cycle, passed through
a 20-gauge needle three times, and then centrifuged at 17,500 g at 4°C
for 10 min. Supernatants were recovered, and protein content was
measured by bicinchoninic acid (BCA) protein assay (Sigma-Aldrich).
Gel electrophoresis and immunoblotting. Protein (100 g/well)
was loaded onto 10% polyacrylamide gels and transferred to nitrocellulose membranes, which were probed and imaged using standard
immunoblotting techniques and detected using a horseradish peroxidase-conjugated secondary antibody (Jackson Immunoresearch, West
Grove, PA) and SuperSignal West Pico PLUS detection reagents
(Thermo Scientific, Rockford, IL). Polyclonal rabbit antibodies against hormone-sensitive lipase (HSL), phospho-HSL (Ser563, Ser565, or
Ser660), and perilipin, as well as a mouse monoclonal antibody against
␤-actin, were obtained from Cell Signaling Technology (Danvers,
MA; catalog nos. 4107, 4139, 4137, 4126, 3470, and 3700, respectively). A mouse monoclonal antibody against phospho-perilipin (human Ser522/mouse Ser517) was obtained from Vala Sciences (San
Diego, CA; catalog no. 4856). Autoradiography films were scanned,
and densitometry was performed using Image Studio software (Li-Cor
Biosciences, Lincoln, NE).
Statistics. GraphPad Prism 6 for Windows software (La Jolla, CA)
was used to calculate means and SE, produce graphs, and determine
statistical significance using unpaired two-tailed t-tests or two-way
ANOVA with Tukey’s multiple comparisons test. Threshold for
significance was set at P ⬍ 0.05.

0
C18:0

C18:1

C16:0

C16:1

Glycerol

Fatty Acids

Fig. 1. Artemisia scoparia (SCO) supplementation in high-fat diet (HFD)
reduces circulating levels of free fatty acids and glycerol. C57BL/6 dietinduced obese (DIO) mice were fed a HFD supplemented with 1% wt/wt SCO
(SCO) or without (CON) ad libitum for 4 wk. Mice were fasted for 4 h, food
was returned to the cages, and mice were euthanized 4 h later. Serum lipids and
glycerol were extracted and analyzed by GC-MS. Data are presented as
means ⫾ SE (n ⫽ 5 mice per group). *P ⬍ 0.05, **P ⬍ 0.01.
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Fig. 2. Artemisia scoparia (SCO) reduces tumor necrosis factor-␣ (TNF␣)induced, but not isoproterenol (ISO)-induced or basal lipolysis in 3T3-L1
adipocytes. Differentiated 3T3-L1 adipocytes, cultured in 6-well plates, were
pretreated for 3 days with SCO at 50 g/ml and overnight with 0.75 nM TNF␣
or equal volumes of their vehicles (DMSO or 0.1% BSA in PBS, respectively).
Culture medium was replaced with lipolysis incubation medium containing 0
or 2 nM or 10 M ISO. Medium was assayed for glycerol and nonesterified
fatty acid (NEFA) concentrations after 2.5 h, and resulting concentrations were
corrected for total RNA measured in harvested cells. Data are displayed as
means ⫾ SE; n ⫽ 3 replicate cell culture wells per condition. Significance
denoted as *P ⬍ 0.05 and **P ⬍ 0.01 (for SCO treatment vs. DMSO control);
#
P ⬍ 0.05, ##P ⬍ 0.01, ###P ⬍ 0.001, ####P ⬍ 0.0001 (for TNF␣ or ISO
treatment vs. basal). Data shown are representative of an experiment that was
repeated 2 (for the ISO treatments) or 3 times (for the TNF␣ treatment).

duces robust activation of lipolysis, it has also been shown to
reduce the expression of genes coding for proteins that promote
lipolysis, such as Adrb3, Lipe/Hsl, and Pnpla2/Atgl (18, 23,
31). In our experiments, TNF␣ treatment of 3T3-L1 adipocytes
produced the expected reductions in expression of these genes,
but the only significant effects of SCO on these genes were
reductions in Atgl and Adrb3 in the absence of TNF␣. Although these effects would be considered antilipolytic, they
cannot explain the effect of SCO on lipolysis, since SCO had
no effect on lipolysis in the absence of TNF␣. Moreover,
reduction in adrenergic signaling would also be expected to
reduce isoproterenol-induced lipolysis, which did not occur
with SCO treatment. Conversely, in the presence of TNF␣,
where SCO does reduce lipolysis it had no effect on Atgl or
Adrb3 expression (Fig. 4).
Since lipolysis rates are largely determined by posttranscriptional and posttranslational regulation of lipolytic and lipid

droplet-associated proteins (reviewed in Ref. 13), we examined
the effects of SCO on perilipin and HSL protein levels and
phosphorylation. Consistent with our gene expression studies
(Figs. 3 and 4), we observed that TNF␣ reduced HSL protein
levels and that SCO did not significantly modulate HSL levels
(Fig. 5A). However, SCO treatment was associated with altered
phosphorylation of two serine residues (Ser563 and Ser660) in
HSL known to increase the enzyme’s activity and lipolysis
rates (1, 16, 56). Although TNF␣ reduced total HSL levels, it
did not alter the amount of HSL phosphorylated at Ser563 (HSL
pSer563). These observations are consistent with reported actions of TNF␣ to increase both HSL phosphorylation and
lipolysis despite reductions in total HSL levels (36, 59, 68, 70).
Although SCO had no effect on HSL pSer563 in unstimulated
conditions, it reduced HSL pSer563 in the presence of TNF␣. A
similar pattern was observed with the other prolipolytic phosphorylation site that we examined, HSL pSer660 (Fig. 5, A and
B). We also studied the phosphorylation of HSL at Ser565,
which inhibits phosphorylation of HSL at Ser563 and is associated with decreased HSL activity (2, 14, 30). TNF␣ produced
a significant reduction in the amount of HSL pSer565, but we
did not observe any modulation by SCO. Perilipin is a major
regulator of lipolysis, as it controls access of HSL to the lipid
droplet, and its phosphorylation is a potent inducer of lipolysis
(39, 63). As shown in the bottom panels of Fig. 5A and C, SCO
had no effect on total perilipin protein levels but produced a
striking reduction in its phosphorylation at Ser517, a prolipolytic modification. In Fig. 5, B and C, bands shown in Fig. 5A
were quantitated by densitometry, and normalized to the loading control, ␤-actin.
DISCUSSION

An ethanolic extract of A. scoparia (SCO) was originally
identified in a screen of botanical extracts that modulated
Table 3. SCO supplementation in high-fat diet significantly
modulates the expression of several lipolysis-related genes
iWAT
Gene

FC

Adrb3
Aqp7
Lipe
Pnpla2
Pde4a
Pde3b

⫺2.83
⫺3.28
⫺2.11
⫺1.36
1.33
1.35

Plin
Npr3
G0s2
Map3k8

⫺1.66
2.70
⫺1.85
2.37

eWAT
P Value

Gene

Antilipolytic regulation
7.58E-05
Mgll
1.05E-04
Adrb3
1.58E-03
Lipe
5.60E-03
Arrb1
0.014
0.031
Prolipolytic regulation
0.014
Adcy9
2.77E-03
Adrb2
2.81E-03
Pde4b
3.65E-03

FC

P Value

⫺2.15
⫺2.16
⫺1.83
⫺1.41

1.26E-03
0.022
0.041
0.045

⫺1.96
1.37
⫺1.28

3.42E-03
0.034
0.043

Diet-induced obese (DIO) mice were fed a high-fat diet with or without
supplementation with 1% wt/wt Artemisia scoparia (SCO) for 4 wk (n ⫽ 4
mice per group). Mice were euthanized, and adipose tissue depots were
harvested and flash-frozen. RNA was purified, and gene expression was
analyzed by microarray. Results were examined for effects of SCO on 36 genes
involved in lipolysis, based on literature searches. Genes significantly regulated by SCO (P ⬍ 0.05) in inguinal (iWAT) and epididymal (eWAT) white
adipose tissue are shown along with their respective fold changes (FC) relative
to controls and P value. Genes are separated based on whether the direction of
observed change would be expected to repress (antilipolytic regulation) or
induce (prolipolytic regulation) lipolysis.

AJP-Endocrinol Metab • doi:10.1152/ajpendo.00177.2018 • www.ajpendo.org
Downloaded from journals.physiology.org/journal/ajpendo at LSU Louisiana State Univ (130.039.060.164) on August 12, 2021.

E1057

SCO INHIBITS LIPOLYSIS

CON - qPCR
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Fig. 3. qPCR validation of Artemisia scoparia (SCO)-regulated genes identified in microarray analysis. For validation, RNA isolated for microarray analysis was
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FC vs CON

adipocyte development in vitro and was later shown to have
metabolically beneficial effects on whole body insulin sensitivity and on adipose tissue function (47, 49). Given the
important role of lipolysis in insulin resistance (22) and the
favorable effects of SCO on insulin sensitivity in vivo, we
hypothesized that SCO might regulate lipolysis. Our studies
revealed that SCO inhibits the levels of both glycerol and FFAs
(NEFAs) both in vivo and in vitro. Mice fed a HFD supplemented with SCO had significantly lower serum levels of
glycerol and all the NEFAs that we examined compared with
HFD controls without SCO supplementation (Fig. 1). These

Fig. 4. Artemisia scoparia (SCO) does not reverse tumor necrosis factor-␣
(TNF␣)-induced changes in the expression of genes involved in lipolysis.
Differentiated 3T3-L1 adipocytes were pretreated for 3– 4 days with SCO at 50
g/ml and/or 0.5 to 0.75 nM TNF␣ or an equal volume of their respective
vehicles (DMSO or 0.1% BSA in PBS). Control (CON) wells were treated
with both vehicles. Cells were harvested, and RNA was isolated, reverse
transcribed, and subjected to qPCR. Target gene data were normalized to the
reference gene Nono. Data are displayed as means ⫾ SE; n ⫽ 3 replicate cell
culture wells per condition. Significance denoted as *P ⬍ 0.01, **P ⬍ 0.0001
(for SCO treatment vs. CON); ##P ⬍ 0.0001 (for TNF␣ treatment vs. CON).
These data are representative of an experiment performed in duplicate.

results suggested that SCO likely reduces lipolysis in adipose
tissue and might affect adipocytes directly. In addition to these
in vivo observations, we found that SCO attenuated TNF␣induced lipolysis but did not substantially affect basal or
isoproterenol-induced release of glycerol and NEFAs in cultured 3T3-L1 adipocytes (Fig. 2).
The association of TNF␣ and adipose tissue inflammation is
well documented. TNF␣ not only promotes insulin resistance
by decreasing the expression of GLUT4 (61), the insulin
receptor, and IRS-1 (60) but also is a potent stimulator of
lipolysis (27). In conditions of obesity and insulin resistance,
TNF␣ can be produced in adipose tissue macrophages and act
in a paracrine manner on adjacent adipocytes to promote
metabolic dysfunction, enhance basal lipolysis, and raise circulating fatty acid levels (11). Increased TNF␣ and circulating
levels of FFAs and their association with insulin resistance
have also been documented in a clinical study (44). Hence, the
ability of SCO to attenuate TNF␣-stimulated lipolysis has
relevance in the context of obesity and Type 2 diabetes.
To investigate the potential mechanisms involved in the
ability of SCO to regulate lipolysis, we performed microarray
analysis and examined the expression of lipolysis-related genes
(Table 1) in both subcutaneous and visceral adipose tissue
samples from an animal study where mice were fed SCO for 4
wk in the presence of a HFD. This analysis yielded equivocal
results. Specifically, few genes were significantly regulated by
SCO; however, not all genes that were altered by SCO were
changed in a manner expected to reduce lipolysis (Table 3).
There are several factors that could account for our observations. First, lipolysis rates are highly regulated at the protein
level through mechanisms such as phosphorylation and protein
stability (43). Although we validated our array results with
qPCR (Fig. 3), it is known that gene expression is not always
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Fig. 5. Artemisia scoparia (SCO) induces antilipolytic changes in phosphorylation of hormone-sensitive lipase (HSL) and perilipin. Differentiated 3T3-L1
adipocytes were pretreated for 3 days with SCO at 50 g/ml and overnight with 0.75 nM tumor necrosis factor-␣ (TNF␣) or equal volumes of their vehicles
(DMSO or 0.1% BSA in PBS, respectively). Control (CON) wells were treated with both vehicles. Culture medium was replaced with lipolysis incubation
medium for 2.5 h for glycerol and nonesterified fatty acid (NEFA) measurements, and then cells were harvested and whole cell extracts were prepared; 100 g
total protein per well were loaded for Western blot analysis. Blot images are shown in A. The HSL Ser563 and Ser660 phosphorylation sites are associated with
enhanced lipolysis, whereas phosphorylation at Ser565 is antilipolytic. B and C: band intensities were quantified by densitometry. All bands were normalized to
the loading control (␤⫺actin). Data are expressed as means ⫾ SE fold change (FC) vs. CON (basal conditions). Significance denoted as ##P ⬍ 0.01 (for effect
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reflective of protein levels or activity. Another consideration is
that, although adipocytes are the prominent cell type found in
adipose tissue, fat tissue is composed of many other cell types
(preadipocytes, immune cells such as lymphocytes and macrophages, and others). Therefore, the gene expression measured in adipose tissue samples reflects mRNA levels in all
adipose tissue cell types. The effects of SCO on gene expression in nonadipocytes may account for some of our microarray
observations (Table 3 and Fig. 3). Of the lipolytic genes that
we examined in cultured adipocytes, only Adrb3 was modulated by SCO, but only in the absence of TNF␣, a condition in
which we did not observe effects of SCO on lipolysis.
In cultured adipocytes, TNF␣ affects the expression and
posttranslational modifications of proteins known to regulate
lipolysis (reviewed in Refs. 13, 55). Hence, we also examined
the effects of TNF␣ and SCO on HSL and perilipin expression
and phosphorylation (Fig. 5). As previously documented,
TNF␣ reduced HSL levels (59) even though it enhanced
lipolysis. SCO did not significantly modulate HSL levels but
did alter the phosphorylation of two serine residues in HSL
known to increase the enzyme’s activity and lipolysis rates (1,

16, 56). Although TNF␣ reduced total HSL levels, it did not
affect phosphorylation of HSL Ser563. Our studies are consistent with evidence that TNF␣ increases HSL phosphorylation
and lipolysis despite its ability to reduce total HSL levels (36,
59, 68, 70). While SCO alone had no effect on HSL pS563 in
basal conditions, phosphorylation at this residue was reduced
in the presence of TNF␣. A similar pattern was observed with
the other prolipolytic phosphorylation site, HSL Ser660. The
phosphorylation of HSL at Ser565 inhibits activation of HSL
and is associated with decreased HSL activity (2, 14, 30).
Although TNF␣ produced a significant reduction in the amount
of HSL pSer565, we did not observe any modulation by SCO.
In terms of HSL, our studies suggest that SCO does not impact
HSL protein levels but can reduce the TNF␣-induced activation of the prolipolytic phosphorylation at Ser563 and Ser660.
Perilipin regulates lipolysis by controlling access of HSL to the
lipid droplet, and its phosphorylation strongly induces lipolysis
(39, 63). Our studies demonstrated that SCO had no effect on
total perilipin protein levels but produced a striking reduction
in its prolipolytic phosphorylation at Ser517 (Fig. 5, A and C).
Phosphorylation at this site has also been shown to be impor-
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tant in human perilipin at Ser522 (62). Clearly, SCO treatment
could affect the ability of TNF␣ to regulate lipolysis by
modulating the phosphorylation of known serine residues in
HSL and perilipin. Previous work from our laboratory has
shown that SCO activates the nuclear receptor PPAR␥ and
modulates expression of its target genes, which, in turn, enhance adipocyte differentiation (47, 49). Effects of SCO on
lipolysis presented in our current study appear to be largely
mediated by posttranslational events rather than at the transcriptional level. Interestingly, inhibition of PPAR␥ has been
shown to be involved in mediating TNF␣’s ability to stimulate
lipolysis, and PPAR␥ agonists inhibit TNF␣-induced lipolysis
(23, 57, 59). In addition, the ability of pioglitazone (a PPAR␥
agonist) to inhibit TNF␣’s effect on lipolysis is independent of
PPAR␥’s adipogenic activity (20). This raises the possibility
that SCO’s effects on adipogenesis and on TNF␣-induced
lipolysis may both be dependent on PPAR␥ activation.
Recently, SCO has been reported to have anti-inflammatory
effects in human mast cells by reducing the levels of TNF␣ and
other inflammatory cytokines (42). These studies also showed
that SCO and one of its constituents, 3,5-dicaffeoyl-epi-quinic
acid, could reduce the nuclear translocation of nuclear factor-B (NF-B). Our studies revealed that SCO attenuated
only TNF␣-induced lipolysis and not basal or adrenergicinduced lipolysis in cultured adipocytes (Fig. 2). Various
mechanisms have been implicated in the ability of TNF␣ to
induce lipolysis, including impairment of insulin signaling (9,
33), repression of the antilipolytic protein G0S2 (23), modulation of the micro-RNA miR-145 (37), and the induction of
extracellular signal-regulated kinase (ERK) (57), as well as the
regulation of cell death-inducing DFFA-like effector c, also
known as fat-specific protein-27 (CIDEC/FSP27) (46). Our
measurements of circulating glycerol and fatty acids were
made in the fed state, when insulin levels are high. Given that
insulin is a potent inhibitor of lipolysis, the insulin-sensitizing
effects of SCO in vivo are likely to contribute to its effects on
lipolysis; however our observation that TNF␣-induced lipolysis in cultured adipocytes is reduced by SCO in the absence of
insulin suggests that SCO may act, at least in part, through
insulin-independent mechanisms. Related to our observations,
a study in human adipocytes has shown that a peptide inhibitor
of IKK (IB kinase) activation effectively blocks the TNF␣mediated nuclear translocation of NF-B (35). Notably, these
studies also show that the ability of TNF␣ to induce lipolysis
is dependent on NF-B activation (35). Collectively, these
reports and our results suggest that the ability of SCO to
attenuate TNF␣-induced lipolysis in cultured adipocytes may
also be related to modulation of NF-B activity. Our in vivo
microarray analysis (Table 3), coupled with our in vitro adipocyte studies (Fig. 4), suggest that modulation of G0S2, a
protein that reduces lipolysis, is not involved in the ability of
SCO to reduce TNF␣-induced lipolysis. Additional studies in
cultured adipocytes indicate that siRNA knockdown of G0S2
did not affect the ability of SCO to regulate lipolysis in 3T3-L1
adipocytes (data not shown). Published studies by other laboratories showing that either anti-inflammatory effects of SCO
(17, 42) or effects of TNF␣ on lipolysis are dependent on
NF-B (35) are supportive of our novel data implicating a
potential role of NF-B in the actions of SCO on adipocytes.
Future studies could be performed to demonstrate a role of
NF-B in this regulation, but these studies will be challenging
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as loss of NF-B expression or activation affects a variety of
adipocyte signaling and inflammatory pathways. To complicate these investigations, there are likely several mechanisms
involved in the ability of SCO to abrogate TNF␣-induced
lipolysis in adipocytes.
Our in vivo studies were performed on HFD-fed mice, in
conditions that are known to promote inflammation in adipose
tissue (49). It should be noted that, although we have not
directly examined macrophage numbers in adipose tissue, our
microarray analysis, as well as unpublished experiments, have
produced no compelling evidence that SCO reduces macrophage infiltration or activation, but rather that SCO attenuates
the response to inflammatory signals in adipocytes. As our in
vitro experiments demonstrate, SCO treatment of cultured
adipocytes renders them less responsive to TNF␣, the primary
macrophage-derived inflammatory mediator in adipose tissue
(4, 8), and these results are consistent with an in vivo scenario
in which SCO may reduce inflammatory responses in adipocytes in the absence of any effects on macrophage numbers
or function. Additional studies would be needed to definitively
address the question of whether SCO treatment can alter
macrophage infiltration or activation in adipose tissue.
In conclusion, our studies have revealed that an extract of
SCO known to have positive effects on various metabolic
parameters in a mouse model of diet-induced obesity (47, 49)
can also reduce serum levels of NEFAs and glycerol (Fig. 1).
Lipolysis is one of several metabolically important functions of
adipose tissue, and it is well known that obesity/type 2 diabetes
is often associated with elevated rates of lipolysis accompanied
by increased circulating levels of glycerol and FFAs (41).
Notably, antilipolytic agents, such as acipimox and atglistatin,
have been proposed as viable therapeutic strategies for improving insulin sensitivity and dyslipidemia (5, 24). Although our
observations do not necessarily indicate a direct effect of SCO
on adipose tissue lipolysis, our results support this notion and
collectively indicate that the ability of SCO to promote metabolic resiliency likely occurs, at least in part, through its ability
to reduce TNF␣-regulated lipolysis. Direct assessment of lipolytic activity from adipose tissue explants ex vivo will be
required to confirm that diet supplementation with SCO reduces lipolysis and to determine any depot-specific differences
in the effects of SCO. Depot-specific differences could also
potentially be assessed through in vitro treatment of primary
adipocytes. Further characterization of TNF␣-induced lipolysis
and its reduction by SCO will also be needed to identify the
mechanisms by which SCO antagonizes TNF␣ action. In
addition, future studies should include efforts to identify the
bioactive compounds present in SCO that regulate lipolysis and
to elucidate other mechanisms involved in the ability of SCO
to promote metabolic health. We propose that the global
epidemics of obesity, type 2 diabetes, and metabolic syndrome
(54) could potentially be tackled by a greater consideration of
botanical-based interventions.
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